Drug manufacturing facility busted in Aydın: number of detainees reaches 6
Translated from Turkish, summarized and contextualized by DistantNews.
TLDR
- Turkish police busted a drug manufacturing facility in Aydın, seizing a large quantity of raw materials and synthetic pills.
- An operation led to the arrest of three suspects initially, with three more apprehended in a subsequent phase.
- The total number of suspects arrested and subsequently jailed in connection with the drug operation has reached six.
In a significant blow to organized crime, anti-drug police in Aydın, Turkey, have dismantled a sophisticated drug manufacturing operation. Acting on intelligence, teams from the Narcotics Crimes Branch of the Provincial Police Department raided a facility within the ASTİM Industrial Zone in the Efeler district, uncovering a substantial illegal drug production hub.
The operation, which commenced with technical and physical surveillance, culminated in a raid on April 22. During the bust, authorities seized approximately 180 kilograms of raw materials used in drug production, 56,000 synthetic pills, and 875,000 ready-to-fill capsules, along with various production equipment. In a secondary seizure, police intercepted a vehicle used by suspects, finding an additional 36,000 synthetic pills.
Following the initial arrests of suspects Ramazan Çökek, Taha Can, and Anıl Güneş, who were subsequently remanded in custody on April 24, the investigation deepened. A second wave of arrests brought in three more individuals identified as M.T., C.D., and D.Ş., all linked to the operation. These three were also brought before the court and subsequently jailed, bringing the total number of individuals arrested and imprisoned in connection with this case to six. This successful operation highlights the Turkish police's ongoing commitment to combating drug trafficking and manufacturing within the country.
Originally published by Cumhuriyet in Turkish. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.